Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Oncology
Erschienen in: Current Treatment Options in Oncology 9/2023

14.06.2023

CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

verfasst von: Elizabeth Sakach, MD, Merve Keskinkilic, MD, Sarah Wood, MD, Madison Canning, MD, Kevin Kalinsky, MDMS

Erschienen in: Current Treatment Options in Oncology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Opinion statement

Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER-2-) metastatic breast cancer (MBC) is the most common subtype of breast cancer. Due to therapeutic advances with molecularly targeted therapies, the prognosis for patients with metastatic disease has improved significantly. The advent of CDK4/6 inhibitors (CDK4/6i) has changed the treatment paradigm for patients with HR+HER2-MBC. CDK4/6i allowed for marked improvement in overall survival, delaying the time to chemotherapy initiation, and improved quality of life for our patients. Efforts are now focused on the best approach(es) for patients after progression on CDK4/6i. Can we further harness the benefit of CDK4/6i in novel combinations at the time of progression? Should we continue CDK4/6i or proceed other novel agents or endocrine therapies? As we advance our treatment strategies for HR+HER2-MBC, there is no longer a one-size-fits-all model, but instead a multifaceted and personalized approach lending to improved outcomes for our patients.
Literatur
1.
McAndrew NP, Finn RS. Clinical review on the management of hormone receptor–positive metastatic breast cancer. JCO Oncology Practice. 2022;18(5):319–27.PubMedCrossRef
2.
•• Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50. Final OS analysis of the randomized, double-blind, placebo-controlled, phase III MONALEESA-2 trial with ribociclib plus letrozole demonstrating OS benefit in the front line.
3.
Neven PFP, Chia S, Jerusalem G, Im S, Petrakova K, Bianchi G, Martin Jimenez M, Nusch A, Sonke GS, de la Cruz merino L, Zarate JP, Wang Y, Chakravatty A, Wang C, Slamon D. editor Updated overall survival (OS) results from the first-line population in the phase III MONALEESA-3 trial of postmenopausal patients with HR+HER2- advanced breast cancer treated with ribociclib + fulvestrant. ESMO Breast Cancer Congres; 2022.
4.
•• M.P. Goetz MT, J. Huober, J. Sohn, O. Tredan, I.H. Park, M. Campone, S.C. Chen, L.M. Manso Sanchez, S. Paluch-Shimon, G. van Hal, A. Shahir, H. Iwata, S. Johnston, editor MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). ESMO Congress; 2022. Second interim OS analysis from the randomized, double-blind, placebo-controlled, phase III MONARCH-3 trial with abemaciclib plus AI demonstrating OS benefit in front line.
5.
•• Lu Y-S, Im S-A, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9. (Exploratory OS analysis with extended follow-up (median 53.5 months) for the randomized, double-blind, placebo-controlled, phase III MONALEESA-7 trial showing consistent OS benefit with ribociclib plus ET in peri/premenopausal patients in the front line.)PubMedCrossRef
6.
Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 2020;183(2):419–28.PubMedPubMedCentralCrossRef
7.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol. 2021;7(12):1791–9.PubMedCrossRef
8.
•• Finn RS, Rugo HS, Dieras VC, Harbeck N, Im S-A, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol. 2022;40(17_suppl):LBA1003-LBA. Planned OS analysis for the randomized, double-blind, placebo-contolled, phase III PALOMA-2 trial with palbociclib and letrozole, where palbo + letrozole had numerically longer OS compared to placebo + letrozole, but the results were not statistically significant.
9.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.PubMedCrossRef
10.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.PubMedCrossRef
11.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III Randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72.PubMedCrossRef
12.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.PubMedCrossRef
13.
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15.PubMedCrossRef
14.
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19.PubMedCrossRef
15.
Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall survival with palbociclib and fulvestrant in women with HR+/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study. Clin Cancer Res. 2022;28(16):3433–42.PubMedPubMedCentralCrossRef
16.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.PubMedCrossRef
17.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–24.PubMedCrossRef
18.
Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.PubMedCrossRef
19.
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015–24.PubMedCrossRef
20.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2019;382(6):514–24.PubMedCrossRef
21.
Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–9.PubMedCrossRef
22.
Sledge Jr GW, Toi M, Neven P, Sohn JH, Inoue K, Pivot X, Okera M, Masuda N, Kaufman PA, Koh H, Grischke E-M, Conte P, Andre V, Bian Y, Shahir A, val Hal G, Llombart-Cussac A. Final overall survival analysis of Monarch 2 : a phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer. San Antonio Breast Cancer Conference; 2022 December 8.
23.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.PubMedCrossRef
24.
• Mayer EL, Ren Y, Wagle N, Mahtani R, Ma CX, DeMichele A, Cristofanili M, Meisel J, Miller KD, Jolly T, Riley E, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block C, Ko N, Patridge AH, Chen WY, DeMeo MK, Attaya V, Okopoebo A, Liu Y, Gauthier E, Bustein H, Regan MM, Tolaney SM. Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. San Antonio Breast Cancer Conference; 2022 December 8; San Antonio, TX. First randomized phase II study demonstrating combination of palbociclib with fulvestrant beyond progression on prior CDK4/6i did not significantly improve PFS compaed to using fulvestrant alone.
25.
• Kalinsky K, Chiuzan C, Singh M, Trivedi M, Novik Y, Tiersten A, Raptis G, Baer L, Young Oh S, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. ASCO Annual Meeting; 2022; Chicago, IL. First randomized, placebo-controlled trial demonstrating significant PFS benefit when switching ET in combination with ribociclib after progression on prior CDK4/6i.
26.
Kalinsky K, Layman RM, Kaufman PA, Graff SL, Bianchini G, Martin M, et al. postMONARCH: a phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. J Clin Oncol. 2022;40(16_suppl):TPS1117-TPS.CrossRef
27.
Rugo H, Bardia A, Cortés J, Curigliano G, Hamilton E, Hurvitz S, et al. Abstract OT2–01–03: ELEVATE: a phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC). Cancer Res. 2023;83(5_Supplement):OT2-01-3-OT2--3.CrossRef
28.
Bidard F-C, Kalinsky K, Cristofanilli M, Bianchini G, Chia SK, Janni W, et al. Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy. Cancer Res. 2022;82(4_Supplement):OT2-11-05-OT2-11–05.CrossRef
29.
Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16.PubMedCrossRef
30.
Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017;22(9):1028–38.PubMedPubMedCentralCrossRef
31.
Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26(20):5310–9.PubMedCrossRef
32.
• Lu YS, Bin Mohd Mahidin El, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Bowels J, Delgar Alfaro T, Wu J, Gao M, Slimane K. Primary results from the randomized phase II right choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. San Antonio Breast Conference; 2022. The first prospective study comparing a CDK4/6i + ET with combination chemotherapy, demonstrating PFS superiority of ribociclib + ET rather than combination chemotherapy in patients with aggressive clinical features or rapidly progressing or highly symptomatic disease, favoring CDK4/6i as the firstline, standard-of-care for patients with visceral crisis.
33.
O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403.PubMedPubMedCentralCrossRef
34.
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway. Cancer Cell. 2018;34(6):893-905.e8.PubMedPubMedCentralCrossRef
35.
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–13.PubMedPubMedCentralCrossRef
36.
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174–93.PubMedPubMedCentralCrossRef
37.
Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget. 2015;6(2):696–714.PubMedCrossRef
38.
Sakurikar N, Thompson R, Montano R, Eastman A. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget. 2016;7(2):1380.PubMedCrossRef
39.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Can Res. 2010;70(5):2085–94.CrossRef
40.
Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855–62.PubMedCrossRef
41.
Mao P, Kusiel J, Cohen O, Wagle N. Abstract PD4–01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer. Cancer Res. 2018;78(4_Supplement):PD4-01-PD4-.CrossRef
42.
Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker AB, Sanders ME, et al. gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. Cancer Res. 2017;77(13_Supplement):1008.CrossRef
43.
O’Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, André F, et al. Circulating tumor DNA Markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer. J Natl Cancer Inst. 2021;113(3):309–17.PubMedCrossRef
44.
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.PubMedPubMedCentralCrossRef
45.
Mao P, Cohen O, Kowalski KJ, Kusiel JG, Buendia-Buendia JE, Cuoco MS, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer FGFR/FGF alterations confer resistance to endocrine therapy. Clin Cancer Res. 2020;26(22):5974–89.PubMedCrossRef
46.
Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, et al. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer. 2015;51(10):1212–20.PubMedCrossRef
47.
Turner N, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez H, et al. Abstract GS3–04: GS3–04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Cancer Res. 2023;83(5_Supplement):GS3-04-GS3-.CrossRef
48.
Wander SA, Keenan JC, Niemierko A, Juric D, Spring LM, Supko J, Vidula N, Isakoff SJ, Ryan L, Padden S, Fisher E, Newton A, Moy B, Ellisen LW, Micalizzi DS, Bardia A. editor Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic beast cancer: results from the phase I TAKTIC trial. SABCS; 2022 December 8, 2022; San Antonio.
49.
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nat Genet. 2019;51(2):207–16.PubMedCrossRef
50.
Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, et al. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019;3(1):18.PubMedPubMedCentralCrossRef
51.
Jhaveri KL, Goldman JW, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, et al. Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): outcomes and biomarker analysis from the SUMMIT trial. J Clin Oncol. 2022;40(16_suppl):1028-.CrossRef
52.
Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, et al. A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER(+)/HER2(-) advanced breast cancer. Clin Cancer Res. 2018;24(15):3510–8.PubMedCrossRef
53.
54.
Bardia A, Bidard F-C, Neven P, Streich G, Montero AJ, Forget F, et al. Abstract GS3–01: GS3–01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. Cancer Res. 2023;83(5_Supplement):GS3-01-GS3-.CrossRef
55.
• Oliveira M, Pominchuck D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, et al. Abstract GS3–02: GS3–02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 2023;83(5_Supplement):GS3–02-GS3-. Randomized, phase II SERENA-2 trial demonstrates next-generation oral SERD, camizestrant, offers meaningful PFS benefit when compared to faslodex in post-menopausal patients who progressed on prior ET, prompting further studies with CDK4/6i and camizestrant in combination in SERENA-4 and SERENA-6.
56.
André F, Im S-A, Neven P, Baird RD, Ettl J, Goetz MP, et al. Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. Cancer Res. 2022;82(4_Supplement):OT2-11-06-OT2-11–06.CrossRef
57.
Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of resistance to CDK4/6 blockade in advanced hormone receptor-positive, HER2-negative breast cancer and emerging therapeutic opportunities. Clin Cancer Res. 2022;28(5):821–30.PubMedCrossRef
58.
Jhaveri K, Harbeck N, Aftimos P, Kim S-B, Pivot X, Saura C, et al. Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Cancer Res. 2022;82(4_Supplement):OT2-11-01-OT2-11–01.CrossRef
59.
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR(+)/HER2(-) advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res. 2021;27(15):4177–85.PubMedPubMedCentralCrossRef
60.
Tolaney SM, Im YH, Calvo E, Lu YS, Hamilton E, Forero-Torres A, Bachelot T, Maur M, Fasolo A, Tiedt R, Nardi L, Stammberger U, Abdelhady AM, Ruan S, Lee SC. Phase Ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus PI3K inhibitor (alpelisib or buparlisib) for HR+ advanced breast cancer. Clin Cancer Res. 2021;27(2):418–28.PubMedCrossRef
61.
Layman R, Wesolowski R, Han H, Specht JM, Stringer-Reasor EM, Dees EC, et al. Abstract PD13–02: phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer. Cancer Research. 2022;82(4_Supplement):PD13-02-PD13-02.CrossRef
62.
Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–48.PubMedCrossRef
Metadaten
Titel
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
verfasst von
Elizabeth Sakach, MD
Merve Keskinkilic, MD
Sarah Wood, MD
Madison Canning, MD
Kevin Kalinsky, MDMS
Publikationsdatum
14.06.2023
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 9/2023
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01109-9

Weitere Artikel der Ausgabe 9/2023

Current Treatment Options in Oncology 9/2023 Zur Ausgabe

ReviewPaper

Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials

ReviewPaper

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer

ReviewPaper

Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review

ReviewPaper

Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors

ReviewPaper

Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives

ReviewPaper

Enhanced Photodynamic Therapy by Improved Light Energy Capture Efficiency of Porphyrin Photosensitizers

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise